Generated by Meeveem AI
"Pioneering immunotherapies and mRNA vaccines for cancer and infectious disease treatment"
BioNTech develops immunotherapies and mRNA vaccines that harness the immune system to fight cancer and infectious diseases. The company combines mRNA cancer immunotherapies, bispecific antibodies, and CAR T cells to address cancer from early to late stages. This approach translates fundamental research into treatments that improve patient outcomes. Founded in 2008 by scientists and physicians, BioNTech operates across discovery, development, and manufacturing. With over 7,800 employees at more than 20 sites worldwide, headquarters in Mainz, Germany, the organisation values unity, passion, and innovation. More than 80 nationalities collaborate to advance breakthrough therapies through scientific rigour and operational excellence.
7807
Team Members
2008
Founded
Biotechnology
Sector
Hybrid
Work Environment
A world where the immune system defeats cancer and infectious diseases through precise, personalised immunotherapies and vaccines that transform treatment standards and extend survival for every patient.
At BioNTech, our mission is to improve the health of people worldwide by harnessing the immune system to develop immunotherapies and vaccines for diseases with high medical need.